Previous Article | Next Article 
Mol Cell Biol, June 1998, p. 3321-3329, Vol. 18, No. 6
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Mutations in the Extracellular Domain Cause RET
Loss of Function by a Dominant Negative Mechanism
Maria Pia
Cosma,1
Monica
Cardone,1
Francesca
Carlomagno,2 and
Vittorio
Colantuoni1,3,*
Dipartimento di Biochimica e Biotecnologie
Mediche and Centro di Ingegneria Genetica,
CEINGE,1 and
Centro di Endocrinologia e
Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia
Cellulare e Molecolare, Facoltà di Medicina e
Chirurgia, Università di Napoli "Federico
II",2 Naples, and
Facoltà di
Farmacia, Università di Reggio Calabria,
Catanzaro,3 Italy
Received 26 February 1998/Accepted 19 March 1998
 |
ABSTRACT |
The RET proto-oncogene encodes a tyrosine kinase
receptor expressed in neuroectoderm-derived cells. Mutations in
specific regions of the gene are responsible for the tumor syndromes
multiple endocrine neoplasia types 2A and 2B (MEN 2A and 2B), while
mutations along the entire gene are involved in a developmental
disorder of the gastrointestinal tract, Hirschsprung's disease (HSCR
disease). Two mutants in the extracellular domain of RET, one
associated with HSCR disease and one carrying a flag epitope, were
analyzed to investigate the impact of the mutations on RET function.
Both mutants were impeded in their maturation, resulting in the lack of
the 170-kDa mature form and the accumulation of the 150-kDa immature
form in the endoplasmic reticulum. Although not exposed on the cell
surface, the 150-kDa species formed dimers and aggregates; this was
more pronounced in a double mutant bearing a MEN 2A mutation. Tyrosine
phosphorylation and the transactivation potential were drastically
reduced in single and double mutants. Finally, in cotransfection
experiments both mutants exerted a dominant negative effect over
protoRET and RET2A through the formation of a
heteromeric complex that prevents their maturation and function. These
results suggest that HSCR mutations in the extracellular region cause RET loss of function through a dominant negative mechanism.
 |
INTRODUCTION |
The RET proto-oncogene
encodes a membrane receptor that expresses tyrosine kinase activity in
tissues of neural crest origin, including the sympathetic ganglia, the
adrenal medulla, thyroid C cells, and the excretory system of the
developing kidney (3, 24, 35, 36). It is also expressed in
tumors originating from neural crest cells, e.g., neuroblastoma,
pheochromocytoma, and thyroid medullary carcinoma (16, 23,
30).
The RET protein shows some structural features that are homologous with
the extracellular domains of cadherins, including putative
Ca2+ binding sites. These repeats are followed by a unique
cysteine-rich tract and a transmembrane segment. The intracellular
region is formed by a bipartite tyrosine kinase functional domain
(35, 36). Glial-cell-line-derived neurotrophic factor (GDNF)
and neurturin have recently been shown to be RET ligands (5, 11, 18, 19). GDNF-deficient mice, in fact, lacked the enteric nervous
system and had abnormalities in the developing kidney similar to those
observed in RET knockout mice (29, 33, 39). Finally, GDNF and neurturin activate RET through intermediate receptors, GDNF receptors
and
. This is a growing family of proteins, anchored through a glycosylphosphatidylinositol (GPI) moiety
on the surfaces of the target cells, that interact with the proper
ligands and induce RET dimerization and activation (5, 18,
19).
Mutations of the RET proto-oncogene have been associated
with several neurochristopathies: multiple endocrine neoplasia types 2A
and 2B (MEN 2A and 2B), familial medullary thyroid carcinoma (FMTC),
and Hirschsprung's disease (HSCR disease) (10, 13, 15, 22,
28). MEN 2 neurochristopathies are autosomal dominant cancer
syndromes: MEN 2A is characterized by medullary thyroid carcinoma
(MTC), pheochromocytoma, and hyperplasia of the parathyroid glands,
while MEN 2B, in addition to MTC and pheochromocytoma, is characterized
by developmental abnormalities without involvement of the parathyroid
glands. FMTC has MTC as the only clinical phenotype (32).
Single-base-pair changes in the codons specifying one of five conserved
cysteine residues in the cysteine-rich region are responsible for 85 to
90% of the MEN 2A cases and the majority of FMTC cases
(13). MEN 2B is caused by a single missense mutation that
involves one of the conserved amino acid residues in the tyrosine
kinase domain of RET (15). In all cases, the result is a
"gain of function" of RET that is believed to be the initiating event that leads to foci of hyperplasia in the target organ and, eventually, to tumor formation. The MEN 2A and MEN 2B alleles behave as
dominant oncogenes in in vitro systems. The MEN 2A mutations constitutively activate the receptor through the formation of covalently linked dimers, independent of the ligand (2, 31). The MEN 2B mutation appears to change the specificities of the substrates that are phosphorylated during intracellular signalling (34).
HSCR disease is a congenital disorder of the autonomic innervation of
the distal gastrointestinal tract that causes its functional obstruction and results in megacolon (26). One HSCR
susceptibility locus was mapped to the pericentromeric region of
chromosome 10 where RET was localized, and, indeed, some
HSCR disease patients have partial deletions of the RET
locus (20, 21). Some other familial or sporadic cases bear
missense, nonsense, or frameshift mutations distributed along the
entire gene that cause amino acid substitutions or protein truncation
(1, 12, 13, 28). In all these cases the receptor is
inactivated, producing a clinical picture of a loss of function. The
RET knockout in mice causes, in fact, a lack of enteric
ganglion cells of the Meissner's and Auerbach's plexuses in
homozygous animals, a clinical picture that is reminiscent of HSCR
disease in humans (33). HSCR mutations of the intracellular
domain of RET introduced into the RET/PTCII chimeric oncogene abolished
RET's biological activity and significantly decreased its kinase
activity. Moreover, they exerted a dominant negative effect on the
RET/PTCII oncogene and on the "activating" MEN 2A mutation (8,
25). Mutations in the extracellular domain of RET impair the
correct maturation of the receptor, its exposure on the cell surface,
and its biological activity (2, 6, 17).
We have analyzed in greater depth the biochemical and biological impact
of two mutations in the outermost region of the extracellular domain of
RET. We demonstrate that these two RET mutants, one carrying
a "natural" HSCR single-base-pair mutation and the other carrying a
stretch of additional amino acids (Flag epitope), were hampered in the
glycosylation process, were retained in the endoplasmic reticulum, and
were sensitive to endoglycosidase-H (Endo-H) cleavage. Similar results
were obtained with a double mutant generated by inserting the Flag
epitope in the RET2A cDNA. The immature 150-kDa species,
although not exposed on the cell surface, was able to form dimers and
high-molecular-weight complexes. The phosphorylation and
transactivation potential of the mutants were low compared to those of
protoRET and RET2A. Finally, in cotransfection-transactivation experiments the mutants interfered with the maturation and function of
the 150-kDa protoRET and RET2A species through the formation of
heteromeric complexes. We suggest that HSCR mutations in the extracellular domain cause RET loss of function by exerting a dominant
negative effect, i.e., inactive heterodimerization between wild-type
and mutated immature proteins results in loss of function.
 |
MATERIALS AND METHODS |
Plasmid constructions.
The pSG-5 expression vector was used
as a recipient plasmid to clone the protoRET full-length
cDNA as an EcoRI-HindIII fragment (8). A DNA fragment carrying the Cys634Arg MEN 2A mutation was obtained by reverse transcription-PCR from a MEN 2A tumor and was
cloned in the same protoRET cDNA, as described elsewhere (8). The mutation at codon 32 associated with HSCR involves the substitution of a serine with a leucine residue and has been described previously (6). To produce the Flag mutants, a
36-bp DNA fragment coding for a polyaspartic acid epitope was cloned at
a unique EagI site present in the 5' region of both
protoRET and RET2A cDNA. The longRET
expression vector carries the cDNA corresponding to the
1,114-amino-acid (aa) protein, with an extension of 51 aa with respect
to the short version of the receptor (13).
Cell culture and transfections.
Cos 7 cells were grown in
Dulbecco's modified Eagle's medium containing 10% fetal calf serum
and were transfected by the calcium phosphate coprecipitation technique
(14). Cells were seeded 5 h before transfection at
106 per 10-cm-diameter plate. Transfections were carried
out with 5 µg of DNA, a quantity that was shown not to overload the
cells or to interfere with the expression of other cellular proteins (8). Cotransfection experiments were performed by
introducing a fixed amount of the TRE-TK-CAT reporter plasmid and
increasing amounts of protoRET, RET2A, HSCR32,
protoRET-Flag, and RET2A-Flag expression vectors.
Alternatively, a fixed amount of protoRET or
RET2A expression constructs was cotransfected with the
various RET mutant expression vectors at 1:1, 1:2, and 1:3
molar ratios. In transactivation-cotransfection experiments, the
mutation-carrying vectors were added to the transfection mixture
containing the TRE-TK-CAT plasmid as the reporter and the
RET2A plasmid as the transactivator at 1:1, 1:2, and 1:3
molar ratios with respect to the RET2A vector. The same
amount of DNA and the same molar ratios of the mutant forms were
employed with the longRET expression vector. Forty-eight
hours after transfection, cells were lysed in a solution of 66 mM HEPES
(pH 7.4), 200 mM NaCl, 1% glycerol, 1% Triton X-100, 2 mM
MgCl2, 6 mM EGTA, 10 mg of aprotinin per ml, 10 mg of
leupeptin per ml, and 2 mM phenylmethylsulfonyl fluoride (JS buffer).
Alternatively, the cells were harvested and assayed for chloramphenicol
acetyltransferase (CAT) enzymatic activity.
Western blot and immunoprecipitation analysis.
Protein
concentration was determined by a modification of the Bradford method
(Bio-Rad). Equal amounts of proteins were separated on a reducing
sodium dodecyl sulfate-7.5% polyacrylamide gel electrophoresis (SDS-7.5% PAGE) gel, transferred onto a membrane, and, subsequently, immunostained with an antibody directed against a peptide from the
carboxy terminus of the RET protein (Santa Cruz Biotechnology, Heidelberg, Germany), an antiphosphotyrosine (anti-p-Tyr)
monoclonal antibody (ICN Biochemicals, Cleveland, Ohio), or an
anti-Flag monoclonal antibody (ICN Biochemicals). The long version of
RET was detected with an immune serum raised against a peptide derived from the unique C terminus extension of the protein. This immune serum
does not recognize the short version of the receptor or the Flag
mutants. Detection was achieved by chemiluminescence with the ECL kit
(Amersham, Little Chalfont, Buckinghamshire, United Kingdom). To detect
RET dimers, electrophoresis was carried out with an SDS-7% PAGE gel
in nonreducing conditions. Immunoprecipitation was accomplished by
mixing 1 mg of protein extracts from transfected cells with
anti-longRET or anti-Flag antibodies. The components of the
immunocomplexes were subsequently identified by Western blotting using
anti-Flag or anti-longRET antibodies, respectively.
Immunofluorescence staining.
Cos cells seeded on glass
coverslips were transfected with protoRET, RET2A,
HSCR32, protoRET-Flag, and RET2A-Flag cDNAs.
Forty-eight hours after transfection, cells were fixed with 3.7%
formaldehyde for 20 min at room temperature, permeabilized with 0.1%
Triton X-100 in phosphate-buffered saline for 5 min at room
temperature, and processed for immunofluorescence staining. Cells were
incubated with rabbit anti-RET serum or mouse anti-Flag monoclonal
antibody for 20 min at room temperature, washed, and treated with
donkey anti-rabbit immunoglobulin G (IgG; Texas Red linked) or with
donkey anti-mouse Ig (Texas Red linked) (Amersham), respectively, for 20 min at room temperature. Pictures were taken with a 63×
magnification lens.
Endo-H digestion.
Equal amounts of protein extracts from
protoRET, RET2A, HSCR32,
protoRET-Flag, and RET2A-Flag cDNA-transfected
cells were denatured at 97°C in a digestion buffer (0.2 M tribasic
sodium citrate [pH 5.5], 0.5% SDS, 1 M
-mercaptoethanol, 0.5 mM
phenylmethylsulfonyl fluoride). Some of the extracts were mixed with
Endo-H enzyme (Boehringer GmbH, Mannheim, Germany), and all were
incubated at 37°C overnight. The products were analyzed by Western
blotting with an anti-RET antibody.
CAT assay.
Forty-eight hours posttransfection, cells were
harvested by scraping, pelleted at 13,000 × g for 10 min,
resuspended in 100 µl of 250 mM Tris (pH 7.5), and lysed by four
cycles of freezing and thawing. The extracts were cleansed of cell
debris by centrifugation at 13,000 × g for 10 min. The CAT
assay was performed with the CAT-Elisa detection kit (Boehringer GmbH)
by following the manufacturer's instructions. Normalization for
variations in transfection efficiency was done by quantitating the
proteins with the Bio-Rad protein assay kit.
 |
RESULTS |
Analysis of RET mutants after transfection into Cos cells.
To
investigate the role that modifications in the outermost part of the
extracellular region of RET play in its cellular localization and
functional activity, two mutants were examined. One mutant carried an
HSCR-associated point mutation at codon 32 that replaces a serine with
a leucine residue (6). The other mutant carried an extra
amino acid sequence, which enabled us to establish whether mutations
different from those associated with HSCR could affect RET function.
The latter mutation was generated by inserting a short DNA segment
coding for an additional polyaspartic acid (Flag epitope) into the 5'
region of protoRET and RET2A cDNAs at a unique EagI restriction enzyme site. These constructs were
designated protoRET-Flag and RET2A-Flag,
respectively. Expression vectors carrying the various cDNAs, driven
either by a viral long terminal repeat (protoRET and the
HSCR32 mutant) or by the simian virus 40 promoter-enhancer cassette
(protoRET, RET2A, protoRET-Flag, and
RET2A-Flag), were transiently transfected into Cos cells, which have negligible levels of endogenous RET protein. Cos cells constitute a reproducible system with which to analyze the effects of
RET mutations (8). Protein extracts were prepared
48 h after transfection and analyzed by Western blotting using
anti-RET polyclonal antibodies raised against a peptide from RET's
carboxy-terminal region. ProtoRET and RET2A
expressed the 150- and 170-kDa species, the immature and mature forms
of the protein, respectively (Fig. 1A,
lane 1, and 1B, lanes 1 and 2). In contrast, only the 150-kDa partially
glycosylated form of the receptor was detected in the extracts from
HSCR32-, protoRET-Flag-, and
RET2A-Flag-transfected cells (Fig. 1A, lane 2, and 1B, lanes
3 and 4).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 1.
Expression of RET mutants in Cos cells. (Top)
Scheme of the short isoform of the RET protein (35). SP,
signal peptide; CAD, cadherin-like domain; CYS, cysteine-rich tract;
TM, transmembrane region; TK, tyrosine kinase domain; 1072, the number
of amino acids in the protein. The positions of the mutants analyzed
are also shown. (A and B) Cos 7 cells were transfected with 5 µg of
each RET construct. Forty-eight hours later, cells were
harvested and protein extracts were prepared. Equal amounts of proteins
(100 µg) from the transfectants (indicated above the lanes) were
loaded in each lane and fractionated on an SDS-7.5% PAGE gel. After
transfer, the proteins were detected by using anti-RET antibodies. The
migration of the mature and immature RET forms is indicated on the
side.
|
|
Subcellular localization of the 150-kDa RET form.
To determine
the subcellular localization of the 150-kDa form, we digested the same
protein extracts from transfected Cos cells with Endo-H. This enzyme
digests the N-linked incomplete oligosaccharides of the proteins before
they are processed to the mature carbohydrate chains in the Golgi
complex. Proteins that have undergone complete glycosylation are
insensitive to Endo-H, whereas partially glycosylated proteins are
sensitive to its action. Equal amounts of protein extracts from
protoRET, RET2A, HSCR32,
protoRET-Flag, and RET2A-Flag cDNA-transfected cells were incubated with or without Endo-H, and the products were
analyzed by Western blotting with anti-RET antibodies. The unique
150-kDa forms of HSCR32, protoRET-Flag, and RET2A-Flag were completely
digested, and a band of about 120 kDa was detected in all samples (Fig.
2, lanes 5 to 10). ProtoRET
and RET2A produced the 170- and 150-kDa forms, and in both
cases only the 150-kDa species was digested, resulting in the same
120-kDa band. As expected, the completely glycosylated 170-kDa form was
not digested (Fig. 2, lanes 1 to 4).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Endo-H sensitivities of the different RET forms. Cos
cells were transfected with the RET constructs indicated
above the lanes and harvested 48 h later. Protein extracts were
prepared and treated with Endo-H or were left untreated. The products
were analyzed on an SDS-7.5% PAGE gel and immunostained with anti-RET
antibodies. The migration of the fully glycosylated and partially
glycosylated proteins and of the digestion product is shown on the
left.
|
|
We performed immunofluorescence assays to verify these results. Cos
cells grown on coverslips were transfected with proto
RET,
RET2A, HSCR32, proto
RET-Flag, and
RET2A-Flag expression vectors,
fixed with formaldehyde,
permeabilized with Triton X-100, and
stained with anti-RET antibodies.
The proto
RET-Flag- and
RET2A-Flag-transfected
cells were stained also with anti-Flag-specific monoclonal antibodies.
The positive immunofluorescence signal detectable in cells transfected
with proto
RET and
RET2A was distributed in the
rough endoplasmic
reticulum through the Golgi complex to the plasma
membrane (Fig.
3A and B). In cells
transfected with HSCR32, proto
RET-Flag, and
RET2A-Flag there was a positive perinuclear staining,
particularly
evident around the nuclear membrane, suggesting a
localization
in the endoplasmic reticulum (Fig.
3C, D, and E). The same
pattern
was obtained with anti-Flag antibodies (Fig.
3F and G). No
staining
was observed with either antibody in mock-transfected or
nonpermeabilized
cells (data not shown).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 3.
Immunofluorescence analysis of the RET mutants. Cos
cells grown on coverslips were transfected with the various
RET constructs as indicated. They were then fixed,
permeabilized, and stained with anti-RET ( RET) (A to E) or anti-Flag
( Flag) (F and G) antibodies.
|
|
The 150-kDa RET species can form homodimers.
To characterize
the biochemical properties of the 150-kDa RET species, protein extracts
from protoRET, RET2A, HSCR32,
protoRET-Flag, and RET2A-Flag cDNA-transfected
cells were fractionated on nonreducing SDS-7% PAGE gel. Equal amounts
of proteins were loaded on twin gels, transferred onto a membrane, and
immunoblotted with anti-RET polyclonal antibodies or anti-Flag
monoclonal antibodies. As expected, a band of about 340 kDa was clearly
detectable in the extracts from RET2A-transfected cells, due
to the disulfide-bonded 170-kDa species (Fig.
4A, lane 2). A band of approximately 300 kDa was barely visible in extracts from cells transfected with
protoRET and was more intense with HSCR32,
protoRET-Flag, and RET2A-Flag (Fig. 4A, lanes 1, 3, 4, and 5). Since the 150-kDa species is the only species produced by
the last three constructs, the band detected can only result from the
dimerization of this form. Similar results were obtained with
protoRET-Flag and RET2A-Flag extracts by using
the anti-Flag antibody (Fig. 4B, lanes 1 and 2). In addition to the
dimer bands, bands corresponding to the monomeric forms of RET were
detected in the lanes corresponding to protoRET, HSCR32, and
protoRET-Flag (Fig. 4A, lanes 1, 3, and 4, and 4B, lane 1) and were
barely visible, if at all, in lanes corresponding to RET2A and
RET2A-Flag (Fig. 4A, lanes 2 and 5, and 4B, lane 2). These forms
appeared slightly smudged because of the long gel run. Finally, very
large protein complexes or aggregates were stained by both anti-RET and
anti-Flag antibodies (Fig. 4). The possibility that GDNF receptor
could participate in these complexes was excluded, as it is not
expressed in Cos cells, as proved by reverse transcription-PCR (data
not shown).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 4.
Dimer formation of the different RET mutants. (A) Equal
amounts of proteins from Cos cells transfected with the
protoRET, RET2A, HSCR32,
protoRET-Flag, and RET2A-Flag constructs were
fractionated on nonreducing SDS-7% polyacrylamide gel, transferred,
and stained with anti-RET ( RET) antibodies. (B) Equivalent protein
extracts from cells transfected with protoRET-Flag and
RET2A-Flag constructs were processed similarly and stained
with anti-Flag ( Flag) antibodies. The migration of the monomers,
dimers, and high-molecular-mass aggregates (h.m.w.a.) is indicated on
the left. The sizes of the dimers were determined on the basis of the
migration of size markers of known molecular weights.
|
|
Phosphorylation of the RET mutants.
Phosphorylation on
tyrosine residues in vivo was then examined to evaluate the kinase
activities of HSCR32, protoRET-Flag, and RET2A-Flag compared to those
of protoRET and RET2A. Equal amounts of proteins from transfected cells
were loaded on twin gels and immunoblotted with anti-RET antibodies or
an anti-p-Tyr monoclonal antibody. Although all different
RET proteins were expressed at high and comparable levels (Fig.
5A, lanes 1 to 5), a variable
phosphorylation was detected. HSCR32 and protoRET-Flag displayed
phosphorylation levels that were lower than the basal one associated
with protoRET (Fig. 5B, lanes 1, 3, and 4); RET2A-Flag was much less
phosphorylated than the activated RET2A (Fig. 5B, lanes 2 and 5).

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 5.
Expression and tyrosine phosphorylation of RET mutants.
Equivalent amounts of protein extracts from cells transfected with the
various constructs were analyzed by Western blotting for the expression
levels of the various forms of RET with anti-RET ( RET) antibodies
(A). The same amounts of proteins were analyzed for tyrosine
phosphorylation with an anti-p-Tyr ( pTyr) antibody (B).
The migration of the 170- and 150-kDa RET monomers is indicated at the
right of both panels.
|
|
Transactivation potentials of the RET mutants.
The
various RET constructs were tested for their abilities to
transactivate a reporter plasmid in transient cotransfection assays.
The TRE-TK-CAT plasmid, in which the TK-CAT gene was fused to a
tetradecanoyl phorbol acetate-responsive element oligonucleotide (TRE),
was used as the target gene. The TRE is the binding site for the AP1
complex and is derived from the collagenase promoter region. Following
the binding of RET with the cognate ligand, the Ras-Raf
mitogen-activated protein kinases constitute, in fact, the major
intracellular signalling pathway activated (40). This cascade of events leads to the formation of Jun-Fos dimers and binding
to responsive elements of the target genes. A constant amount of the
reporter plasmid was cotransfected with different ratios (1:1, 1:2, and
1:3) of the various RET mutants. A dose-response curve that
was repeatedly observed with different DNA preparations and in at least
three independent experiments was obtained (Fig. 6). The empty vectors alone showed no
activity; protoRET caused a basal level of induction, while
RET2A induced a level of CAT activity about fourfold higher
than that induced by protoRET. The HSCR32 mutant and the
Flag-containing constructs did not transactivate the reporter plasmid.
The HSCR32 data confirmed in our system the findings obtained with PC12
cells (6).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
Transactivation abilities of RET mutants. Cos
cells were transfected with a constant amount (5 µg) of the
TRE-TK-CAT reporter gene and three different molar ratios (from left to
right, for each expression vector, 1:1, 1:2, and 1:3) of each of the
expression vectors for protoRET, RET2A, HSCR32,
protoRET-Flag, and RET2A-Flag. Each CAT activity
is reported as relative induction and represents the mean of at least
three independent experiments performed with different DNA
preparations. Standard deviations are indicated by error bars.
|
|
Dominant negative effect of the RET mutants.
To
establish whether HSCR32 and the Flag mutants exert a dominant negative
effect, we performed transient cotransfections with a fixed amount of
protoRET and three molar ratios of the various mutants (1:1,
1:2, and 1:3). protoRET and HSCR32 mutant plasmids,
individually transfected, produced the 170- and 150-kDa bands and the
150-kDa band, respectively (Fig. 7A,
lanes 1 and 2). When protoRET and HSCR32 were cotransfected,
the mature 170-kDa form was detected at low levels at the 1:1 ratio and
completely disappeared with the increase of the cotransfected mutant
plasmid (Fig. 7A, lanes 3 to 5). The 150-kDa band, on the other hand, markedly increased. Transfections with protoRET and
protoRET-Flag plasmids, carried out under the same
experimental conditions, produced similar results. In this case also,
cotransfections of the mutant plasmid caused a drastic reduction of the
170-kDa form even at the 1:1 ratio and complete abrogation at higher
proportions (Fig. 7B, lanes 1 to 5). Cotransfection of
protoRET with increasing amounts of an empty vector
did not affect the accumulation of the 170-kDa form, excluding promoter
competition effects. In contrast, the amount of the mature form
increased proportionally with the amount of proteins loaded in each
lane (Fig. 7, panel C).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 7.
HSCR32 and protoRET-Flag mutants exert a
dominant negative effect over protoRET. (A) Cos cells were
cotransfected with 5 µg of protoRET and 5, 10, and 15 µg
of protoRET-Flag expression vectors. Parallel transfections
were carried out with 5 µg of protoRET and
protoRET-Flag expression vectors alone. A Western blot
analysis was performed with increasing amounts of proteins from the
transfected cells. Lane 1, protoRET (50 µg); lane 2, HSCR32 (50 µg); lanes 3 to 5, protoRET and HSCR32 at ratios of 1:1 (100 µg)
(lane 3), 1:2 (150 µg) (lane 4), and 1:3 (200 µg) (lane 5). After
the immunoblotting, the RET species were stained with anti-RET
antibodies. The migration of the 170- and 150-kDa RET monomers is
indicated. (B) Western blot analysis performed as described for panel A
on different amounts of protein extracts from cells individually
transfected with protoRET and protoRET-Flag
expression plasmids (lanes 1 and 2) or cotransfected at three molar
ratios (lanes 3 to 5). The migration of the 170- and 150-kDa RET
monomers is indicated. (C) Western blot analysis performed on protein
extracts from cells individually transfected with protoRET
or an empty vector (lanes 1 and 2) or cotransfected in three molar
ratios (lanes 3 to 5). The RET species were identified by
immunoblotting with anti-RET antibodies. (D) Western blot analysis
performed as described for panel A on different amounts of proteins
from cells transfected with protoRET and HSCR32 alone (lanes
1 and 2) or with a combination of a fixed amount of HSCR32 and three
ratios of protoRET expression vector (lanes 3 to 5). In
lanes 6 and 7 extracts from cells transfected with an empty vector
alone or cotransfected with HSCR32 and an empty vector at a 1:3 ratio
are shown. The RET species were identified with anti-RET antibodies.
(E) Western blot analysis of protein extracts from cells transfected
with protoRET and protoRET-Flag expression
vectors alone (lanes 1 and 2) or cotransfected with a fixed amount of
protoRET-Flag and three proportions of protoRET
(lanes 3 to 5). Extracts from cells transfected with an empty vector or
with protoRET-Flag and an empty vector at a 1:3 ratio were
loaded in lanes 6 and 7. The RET species were identified with anti-RET
antibodies.
|
|
The same extracts were analyzed for the maturation of an endogenous
protein to control the glycosylation process. The

subunit
of the
membrane-bound ATPase is a membrane protein only in its
fully
glycosylated form. This 55-kDa protein was detected as a
single band of
the expected size in all extracts analyzed, ruling
out the possibility
that the glycosylation machinery was saturated
or slowed down by
overproduction of the transfected proteins (data
not shown). To confirm
that the data obtained were not due to
an overload of the cells with
exogenous proteins but rather to
a specific heterodimerization event,
the converse experiment was
performed. Constant amounts of HSCR32 or
proto
RET-Flag were cotransfected
with increasing ratios of
proto
RET. A proportional increase of
the 170-kDa band
occurred in the lanes corresponding to the cotransfectants,
together
with an increase of the 150-kDa band (Fig.
7D and E,
lanes 1 to 5).
This effect was specific because cotransfection
of an empty vector or a
plasmid expressing an unrelated protein
did not produce the 170-kDa
band (Fig.
7D and E, lanes 6 and 7).
We also demonstrated that the
formation of the RET2A 170-kDa form
was impeded in cotransfections with
increasing amounts of the
RET2A-Flag mutant expression
vector, as shown for proto
RET (Fig.
8A, lanes 1 to 5).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 8.
RET2A-Flag mutant exerts a dominant negative
effect over an activated RET2A. (A) Western blot analysis of
equivalent protein extracts from cells transfected with the
RET2A and RET2A-Flag expression vectors alone
(lanes 1 and 2) or together at three different molar ratios (lanes 3 to
5). The RET forms were stained with anti-RET antibodies. The migration
of the 170- and 150-kDa RET monomers is indicated. (B and C)
Transactivation-cotransfection assay performed with the TRE-TK-CAT
plasmid (2 µg) as the reporter, the RET2A carrying vector
as the transactivator at a 1:3 ratio (6 µg), and the
RET2A-Flag (B)- or HSCR32 (C)-containing plasmid in three
molar ratios with respect to RET2A plasmid (6, 12, and 18 µg). An empty vector was used as the negative control of the
experiments. CAT activity is reported as relative induction and
represents the mean of at least three independent experiments performed
with different DNA preparations. The standard deviation is indicated by
error bars. +, species is present; , species is absent.
|
|
To correlate the maturation block with the biological activities of the
various RET forms, we performed transactivation-cotransfection
experiments. The TRE-TK-CAT and the
RET2A plasmids were used
as
the target and transactivating vectors, respectively. The
RET2A
construct was the only one able to transactivate a
reporter gene
and was used at the 1:3 ratio shown before to produce the
highest
level of induction (Fig.
6). The addition of
RET2A-Flag vector
to the cotransfection mixture at 1:1, 1:2,
and 1:3 ratios, with
respect to the
RET2A vector, nearly
abolished the CAT activity
of the target gene (Fig.
8B). Similar
results were obtained with
HSCR32 (Fig.
8C) and
proto
RET-Flag (data not shown) expression
vectors. Taken
together these results demonstrate a clear correlation
between the lack
of production of the 170-kDa form and the loss
of RET biological
function.
Finally, to demonstrate that both the wild-type and mutant RET forms
were expressed during the course of the experiments,
we transfected Cos
cells with plasmids expressing proteins that
could differentially be
identified by specific antibodies. This
strategy allows the
determination of the type and the amount of
each protein synthesized
from the transfected cDNAs. The proto
RET-Flag
expression
vector was cotransfected in three increasing molar
ratios (1:1, 1:2,
and 1:3) with a constant amount of a plasmid
expressing
long
RET. This protein contains an additional stretch
of 51 aa at its C terminus (
13) and is recognized by a specific
antiserum that does not identify either protoRET or protoRET-Flag.
Long
RET and the Flag mutant cDNAs were also transfected
alone,
as controls (Fig.
9A and B, lanes
1 and 2). Protein extracts from
the transfected cells were loaded as
described above on twin gels,
fractionated by SDS-PAGE, transferred,
and immunostained with
anti-longRET or anti-Flag antibodies. The
anti-RET antibodies
recognized both longRET species: the 170-kDa form
was already
diminished at the 1:1 ratio and completely disappeared at
the
1:2 and 1:3 ratios (Fig.
9A, lanes 3 to 5); the 150-kDa form was
present and increased in the extracts at the 1:2 and 1:3 ratios.
The
anti-Flag antibodies recognized only the 150-kDa form produced
by the
Flag mutant, which increased with the amount of the proteins
loaded
(Fig.
9B, lanes 3 to 5; see also the experiments described
above).
Similar results were obtained in cotransfections of long
RET cDNA with HSCR32 and
RET2A-Flag expression vectors (data not
shown).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 9.
LongRET and the Flag mutant are coexpressed and form
heterodimers in cotransfected cells. (A and B) Cos cells were
cotransfected with 5 µg of longRET and 5, 10, and 15 µg
of protoRET-Flag expression vectors. Parallel transfections
were carried out with 5 µg of longRET and
protoRET-Flag expression vectors alone. A Western blot
analysis was performed with increasing amounts of proteins from the
transfected cells. Lane 1, longRET (50 µg); lane 2, protoRET-Flag (50 µg); lanes 3 to 5, protoRET and protoRET-Flag at a 1:1 ratio (100 µg) (lane 3), at a 1:2 ratio (150 µg) (lane 4), and at a 1:3 ratio
(200 µg) (lane 5). After the immunoblotting, the RET species were
stained with either anti-longRET- or anti-Flag-specific antibodies, as
indicated. The migration of the 170- and 150-kDa RET monomers is shown.
(C) Immunoprecipitation and immunoblotting experiments. One milligram
of protein extracts from Cos cells transfected with longRET
and protoRET-Flag expression vectors alone or cotransfected
at a 1:1 molar ratio was subjected to immunoprecipitation with
anti-longRET ( longRET) (lanes 1, 2, 5, and 6) or anti-Flag ( Flag)
antibodies (lanes 3, 4, 7, and 8). The anti-longRET immunocomplexes
were subsequently stained with the same antibodies (lanes 1 and 5) or
with the anti-Flag antibodies (lanes 2 and 6). The anti-Flag
immunoprecipitates were stained with the same antibodies (lanes 3 and
7) or with anti-longRET antibodies (lanes 4 and 8). The migration of
the 170- and 150-kDa RET monomers is shown.
|
|
To investigate whether longRET and the Flag mutant were capable of
interacting and forming heterodimers, protein extracts
from
cotransfected Cos cells were immunoprecipitated with anti-longRET
or anti-Flag antibodies. The complexes were subsequently
immunoblotted
with anti-Flag or anti-longRET antibodies,
respectively. In the
anti-longRET immunoprecipitates derived from
cotransfected Cos
cells, the immunoblot with the same antibodies
identified a single
band of 150 kDa (Fig.
9C, lane 5). A similar band
was recognized
by the anti-Flag antibodies (lane 6). In contrast, when
the extracts
from cells transfected with the long
RET
construct alone were immunoprecipitated
and immunostained with the same
antibodies, both 170- and 150-kDa
longRET forms were recognized (lane
1). The anti-Flag antibodies
did not recognize any band in these
immunocomplexes (lane 2).
In the reverse experiment, when the extracts
derived from the
same cotransfected cells were immunoprecipitated and
immunoblotted
with the anti-Flag antibodies, a single band of 150-kDa
was detected;
immunoblotting with the anti-longRET antibodies revealed
also
a 150-kDa band (lanes 7 and 8). Protein extracts from the
protoRET-Flag
single transfectant immunoprecipitated and immunoblotted
with
the anti-Flag antibodies recognized only the 150-kDa species (lane
3); no bands were recognized by the anti-longRET antibodies on
the same
immunocomplexes (lane 4). These results demonstrate that
the 150-kDa
mutant form is capable of heterodimerizing with the
150-kDa wild-type
species.
 |
DISCUSSION |
Role of the extracellular region in the maturation of the RET
receptor.
We investigated the effects of two mutations located at
the extreme N terminus of the extracellular region of the product of
the RET proto-oncogene on the biochemical and biological
activity of the whole receptor. The HSCR32 mutation affects an amino
acid residue which is highly conserved among species and is associated with a long form of HSCR (6, 17). In this respect, HSCR32 is
similar to all other mutants associated with this disease. We asked
whether mutants carrying an insertion at the N-terminal part, such as
the Flag-containing mutant analyzed here, could have similar effects.
The two mutants behaved similarly: they inhibited the production of the
mature 170-kDa form and its exposure on the cell membrane by
interfering with the glycosylation process. The immature 150-kDa form
accumulated in the endoplasmic reticulum, as shown also by
immunofluorescence studies and by the sensitivity of this form to
Endo-H digestion. Other HSCR mutants with mutations in the
extracellular domain (6, 17) and at the putative calcium binding site of the cadherin-like domain interfered with RET maturation (2). From these data it appears that the correct folding of the extracellular region plays a crucial role in the maturation, in the
intracellular transport, and, ultimately, in the function of RET. This
region, with the exclusion of the cysteine-rich tract, behaves as an
independent structural and functional domain, because the maturation
block was detected also with the double mutant RET2A-Flag, a
RET mutant with a MEN 2A mutation.
The 150-kDa species can form homodimers.
The results of this
study show that the 150-kDa RET form was able to form dimers before its
insertion into the plasma membrane and in the absence of the ligand.
Therefore, accumulation of the protein in the endoplasmic reticulum
seems to facilitate dimerization, and the larger the amount of protein
retained, the greater the number of dimers formed. In fact, dimers were
barely detectable in protoRET, were abundant in protoRET-Flag, and were
more abundant in RET2A-Flag. This increase is probably a result of
their higher degree of stability brought about by the covalent bonds
generated by the mispaired cysteine residues. As a consequence, the
monomeric forms, practically undetectable in the RET2A
constructs, were still evident in the protoRET plasmid. The
data suggest that the processing of the receptor may involve a
dimerization step of the 150-kDa form. We also detected
high-molecular-weight aggregates, the biological significance of which
is not yet clear. More experiments are required to elucidate their
origin and composition. They were, in fact, resistant to heat and to
denaturing conditions; disulfide bonds and noncovalent interactions may
be responsible for their formation, and other proteins may participate
in these complexes.
Intracellular dimerization has been reported for the products of other
activated oncogenes and is due to protein domains artificially
fused
after translocation or genomic rearrangements.
RET/PTCII
codes for a protein in which the RET tyrosine kinase domain is
fused to
the N terminus from the R1

regulatory subunit of the
protein kinase
A that provides the structural motifs for intracellular
dimerization
(
4). Also, the
Trk gene is activated in several
tumors via a mechanism of gene rearrangement, in which its kinase
domain becomes juxtaposed to heterologous sequences, such that
the
resulting protein can form intracellular homodimers (
9).
A
structurally altered form of the
Ron gene product is not
exposed
on the cell surface; the products are retained intracellularly
as dimers and oligomers stabilized by intermolecular disulfide
bonds
(
7). Finally, an intragenic deletion of the
Met
oncogene
leads to the formation of a mutant protein that has an uneven
number of cysteine residues in the extracellular domain and that
is
altered in its folding and blocked in its maturation (
27).
In all these cases, the mutant proteins display constitutive tyrosine
phosphorylation and cause the expressing cells to become transformed.
The mutations of the
RET proto-oncogene described in this
report
behave differently.
Phosphorylation, transactivation potentials, and biological effects
of the mutants analyzed.
The mutations analyzed in this study
hampered the kinase activity of the receptor. HSCR32 and the Flag
mutants showed low-level, if any, tyrosine phosphorylation compared
with the basal level of phosphorylation of protoRET and with the high
level of phosphorylation of RET2A. This low level of phosphorylation
activity was associated with a lack of the transactivation potential
and therefore with a lack of function. RET2A, in fact,
induced CAT activity, while protoRET caused only a slight
increase; HSCR32, protoRET-Flag, and RET2A-Flag
showed no significant induction. The low level of phosphorylation
activity of the HSCR32 and Flag constructs may be attributed to inter-
and intramolecular phosphorylation of the 150-kDa species accumulated
as dimers in the endoplasmic reticulum. The 150-kDa dimers, however,
were not active in transactivation (Fig. 6). The low levels of
phosphorylation and transactivation potential associated with protoRET
could, instead, be ascribed to the mature 170-kDa species and to its
low level of intrinsic kinase activity (37).
The cotransfection experiments demonstrated that the
RET
mutants interfere with the formation of the 170-kDa species derived
from the cotransfected proto
RET and
RET2A
plasmids. This effect
was very intense at a ratio of 1:1, suggesting
that, already in
this condition, the mutant RET impairs the synthesis
of the mature
170-kDa species from the wild-type allele and its
exposure on
the membrane. At higher proportions of the mutant plasmids,
the
mature 170-kDa form completely disappeared. As shown by the reverse
experiments and by the controls, the effects observed were specifically
due to the mutant RET species produced over the wild-type form.
The
cotransfection and immunoprecipitation experiments with the
long
RET expression vector demonstrated that the mutant RET
species
were expressed together with the wild-type forms and were
capable
of interacting and forming a heteromeric complex with the
corresponding
150-kDa form from the normal allele. The
transactivation-cotransfection
experiments finally demonstrated that
the heteromeric complexes
did not transactivate a target gene:
RET2A CAT activity was diminished
to complete abrogation in
the presence of increasing amounts of
the mutants. The maturation block
thus correlates with the reduction
and abolition of the biological
function of the RET receptor.
On the basis of the data reported in this manuscript, we propose a
molecular mechanism to explain the pathogenesis of the
HSCR disease
cases due to mutations in the extracellular region
of RET. The 150-kDa
mutant form accumulates in the endoplasmic
reticulum and
heterodimerizes with the RET precursors derived
from the normal allele.
These are "sequestered" by the mutant
forms and are impeded from
maturing fully and from being inserted
into the cell membrane. The
mutant HSCR forms, then, act as dominant
negative forms overwhelming
the wild-type RET protein and preventing
it from functioning. This
effect is very evident at a 1:1 ratio,
a condition similar to the
heterozygous state of HSCR disease
patients, suggesting that an active
RET receptor is critical for
the full development of the enteric
ganglia in humans. The mechanism
proposed here for HSCR mutations in
the extracellular region of
RET parallels the one proposed for
intracytoplasmic HSCR mutations
(
8,
25). In conclusion, all
HSCR disease cases in which RET
is involved are caused by mutations
scattered throughout the associated
gene that result in a clinical
picture typical of loss of function
of the receptor by a mechanism of
negative dominance.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the CNR, Progetto
Finalizzato ACRO, Sottoprogetto 4, and from Associazione Italiana per
la Ricerca sul Cancro (AIRC).
We thank V. E. Avvedimento, S. Bonatti, and M. Grieco for
suggestions and critical reading of the manuscript. We thank J. Gilder
for editing the text. The technical assistance of Maurizio Lamagna is
gratefully acknowledged.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dipartimento di
Biochimica e Biotecnologie Mediche, Facoltà di Medicina e
Chirurgia, Università di Napoli, "Federico II," Via Sergio
Pansini, 5, 80131 Naples I, Italy. Phone: 39 81 746 3735. Fax: 39 81 746 3074. E-mail: colantuoni{at}dbbm.unina.it.
 |
REFERENCES |
| 1.
|
Angrist, M.,
S. Bolk,
B. Thiel,
E. G. Puffemberger,
R. M. W. Hofstra,
C. H. C. M. Buys,
D. T. Cass, and A. Chakravarti.
1995.
Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease.
Hum. Mol. Genet.
4:821-830[Abstract/Free Full Text].
|
| 2.
|
Asai, N.,
T. Iwashita,
M. Matsuyama, and M. Takahashi.
1995.
Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.
Mol. Cell. Biol.
15:1613-1619[Abstract].
|
| 3.
|
Avantaggiato, V.,
N. A. Dathan,
M. Grieco,
N. Fabien,
D. Lazzaro,
A. Fusco,
A. Simeone, and M. Santoro.
1994.
Developmental expression of the RET proto-oncogene.
Cell Growth Differ.
5:305-311[Abstract].
|
| 4.
|
Bongarzone, I.,
N. Monzini,
M. G. Borrello,
C. Carcano,
G. Ferraresi,
E. Arighi,
P. Mondellini,
G. Della Porta, and M. A. Pierotti.
1993.
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI of cyclic AMP-dependent protein kinase A.
Mol. Cell. Biol.
13:358-366[Abstract/Free Full Text].
|
| 5.
|
Buj Bello, A.,
J. Adu,
L. G. Pinon,
A. Horton,
J. Thompson,
A. Rosenthal,
M. Chinchetru,
V. L. Buchman, and A. M. Davies.
1997.
Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase.
Nature
387:721-724[Medline].
|
| 6.
|
Carlomagno, F.,
G. De Vita,
M. T. Berlingieri,
V. de Franciscis,
R. M. Melillo,
V. Colantuoni,
M. H. Kraus,
P. P. Di Fiore,
A. Fusco, and M. Santoro.
1996.
Molecular heterogeneity of RET loss of function in Hirschsprung's disease.
EMBO J.
15:2717-2725[Medline].
|
| 7.
|
Collesi, C.,
M. Santoro,
G. Gaudino, and P. Comoglio.
1996.
A splicing variant of the RON transcript induces contitutive tyrosine kinase activity and an invasive phenotype.
Mol. Cell. Biol.
16:5518-5526[Abstract].
|
| 8.
|
Cosma, M. P.,
L. Panariello,
L. Quadro,
N. A. Datan,
O. Fattoruso, and V. Colantuoni.
1996.
A mutation in the RET proto-oncogene in Hirschsprung's disease affects the tyrosine kinase activity associated with multiple endocrine neoplasia type 2A and 2B.
Biochem. J.
314:397-400.
|
| 9.
|
Coulier, F.,
R. Kumar,
M. Ernst,
R. Klein,
D. Martin-Zanca, and M. Barbacid.
1990.
Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain.
Mol. Cell. Biol.
10:4202-4210[Abstract/Free Full Text].
|
| 10.
|
Donis-Keller, H.,
S. Dou,
D. Chi,
K. M. Carlson,
K. Toshima,
T. C. Lairmore,
J. R. Howe,
P. Goodfellow, and S. A. Wells.
1993.
Mutations in the RET proto-oncogene are associated with MEN2A and FMTC.
Hum. Mol. Genet.
2:851-856[Abstract/Free Full Text].
|
| 11.
|
Durbec, P.,
C. V. Marcos Gutierrez,
C. Kilkenny,
M. Grigoriou,
K. Wartiowaara,
P. Suvanto,
D. Smith,
B. Ponder,
F. Costantini,
M. Saarma,
H. Sariola, and V. Pachnis.
1996.
GDNF signalling through the Ret receptor tyrosine kinase.
Nature
381:789-793[Medline].
|
| 12.
|
Edery, P.,
S. Lyonnet,
L. M. Mulligan,
A. Pelet,
E. Dow,
L. Abel,
S. Holder,
C. Nihoul,
B. A. J. Ponder, and A. Munnich.
1994.
Mutations of the RET proto-oncogene in Hirschsprung's disease.
Nature
367:378-380[Medline].
|
| 13.
|
Eng, C., and L. M. Mulligan.
1997.
Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease.
Hum. Mutat.
9:97-109[Medline].
|
| 14.
|
Graham, F. L., and A. J. van der Eb.
1973.
A new technique for the assay of infectivity of human adenovirus 5 DNA.
Virology
52:456-467[Medline].
|
| 15.
|
Hofstra, R. M. W.,
R. M. Landsvater,
I. Ceccherini,
R. P. Stulp,
T. Stelwagen,
Y. Luo,
B. Pasini,
J. W. M. Hoppener,
H. K. Ploos van Amstel,
G. Romeo,
C. J. M. Lips, and C. H. C. M. Buys.
1994.
A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
Nature
367:375-376[Medline].
|
| 16.
|
Ikeda, I.,
Y. Ishizaka,
T. Tahira,
T. Suzuki,
M. Onda,
T. Sugimura, and M. Nagao.
1990.
Specific expression of the RET proto-oncogene in human neuroblastoma cell lines.
Oncogene
5:1291-1296[Medline].
|
| 17.
|
Iwashita, T.,
H. Murakami,
N. Asai, and M. Takahashi.
1996.
Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extracellular domain.
Hum. Mol. Genet.
5:1577-1580[Abstract/Free Full Text].
|
| 18.
|
Jing, S.,
D. Wen,
Y. Yu,
P. L. Holst,
Y. Luo,
M. Fang,
R. Tamir,
L. Antonio,
Z. Hu,
R. Cupples,
J. C. Louis,
S. Hu,
B. W. Altrock, and G. M. Fox.
1996.
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.
Cell
85:1113-1124[Medline].
|
| 19.
|
Klein, R. D.,
D. Sherman,
W. H. Ho,
D. Stone,
G. L. Bennett,
B. Moffat,
R. Vandlen,
L. Simmons,
Q. Gu,
J. A. Hongo,
B. Devaux,
K. Poulsen,
M. Armanini,
C. Nozaki,
N. Asai,
A. Goddard,
H. Phillips,
C. E. Henderson,
M. Takahashi, and A. Rosenthal.
1997.
A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.
Nature
387:717-721[Medline].
|
| 20.
|
Luo, Y.,
I. Ceccherini,
B. Pasini,
I. Matera,
M. P. Bicocchi,
V. Barone,
R. Bocciardi,
H. Kaariaiainen,
D. Weber,
M. Devoto, and G. Romeo.
1993.
Close linkage with the RET proto-oncogene and boundaries of deletion mutants in autosomal dominant Hischsprung disease.
Hum. Mol. Genet.
11:1803-1808.
|
| 21.
|
Martucciello, G.,
M. P. Bicocchi,
P. Dodero,
M. Lerone,
M. S. Cirillo,
A. Puliti,
G. Gimelli,
G. Romeo, and V. Jasonni.
1992.
Total colonic aganglionosis associated with interstitial deletion of the long arm of chromosome 10.
Pediatr. Surg. Int.
7:308-310.
|
| 22.
|
Mulligan, L. M.,
J. B. Kwok,
C. S. Healey,
M. J. Elsdon,
C. Eng,
E. Gardner,
D. R. Love,
S. E. Mole, and J. K. Moore.
1993.
Germline mutations of the RET protooncogene in multiple endocrine neoplasia type 2A families.
Nature
363:458-460[Medline].
|
| 23.
|
Nakamura, T.,
Y. Ishizaka,
M. Nagao,
M. Hara, and T. Ishikawa.
1994.
Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin.
J. Pathol.
172:255-260[Medline].
|
| 24.
|
Pachnis, V.,
B. Mankoo, and F. Costantini.
1993.
Expression of the c-ret proto-oncogene during mouse embryogenesis.
Development
119:1005-1017[Abstract].
|
| 25.
|
Pasini, B.,
M. G. Borrello,
A. Greco,
I. Bongarzone,
Y. Luo,
P. Mondellini,
L. Alberti,
C. Miranda,
E. Arighi,
R. Bocciardi,
M. Seri,
V. Barone,
M. T. Radice,
G. Romeo, and M. A. Pierotti.
1995.
Loss of function effect of RET mutations causing Hirschsprung disease.
Nat. Genet.
10:35-40[Medline].
|
| 26.
|
Passarge, E.
1967.
The genetics of Hirschsprung's disease.
N. Engl. J. Med.
276:138-141.
|
| 27.
|
Rodriguez, G. A.,
M. A. Naujokas, and M. Park.
1991.
Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing.
Mol. Cell. Biol.
11:2962-2970[Abstract/Free Full Text].
|
| 28.
|
Romeo, G.,
P. Ronchetto,
Y. Luo,
V. Barone,
M. Seri,
I. Ceccherini,
B. Pasini,
R. Bocciardi,
M. Lerone,
H. Kaariainen, and G. Martucciello.
1994.
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.
Nature
367:377-378[Medline].
|
| 29.
|
Sanchez, M. P.,
I. Silos Santiago,
J. Frisen,
B. He,
S. A. Lira, and M. Barbacid.
1996.
Renal agenesis and the absence of enteric neurons in mice lacking GDNF.
Nature
382:70-73[Medline].
|
| 30.
|
Santoro, M.,
R. Rosati,
M. Grieco,
M. T. Berlingieri,
L. C. D'Amato,
V. De Franciscis, and A. Fusco.
1990.
The RET proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.
Oncogene
5:1595-1598[Medline].
|
| 31.
|
Santoro, M.,
F. Carlomagno,
A. Romano,
D. P. Bottaro,
N. A. Dathan,
M. Grieco,
A. Fusco,
G. Vecchio,
B. Matoskova,
M. H. Kraus, and P. P. Di Fiore.
1995.
Germ-line mutations of MEN2A and MEN2B activate RET as a dominant transforming gene by different molecular mechanisms.
Science
267:381-383[Abstract/Free Full Text].
|
| 32.
|
Schimke, R. N.
1984.
Genetic aspects of multiple endocrine neoplasia.
Annu. Rev. Med.
35:25-31[Medline].
|
| 33.
|
Schuchardt, A.,
V. D'Agati,
L. L. Blomberg,
F. Costantini, and V. Pachnis.
1994.
The c-ret receptor tyrosine kinase gene is required for the development of the kidney and enteric nervous system.
Nature
367:380-383[Medline].
|
| 34.
|
Songyang, Z.,
K. L. Carraway III,
M. J. Eck,
S. C. Harrison,
R. Feldman,
M. Mohammadi,
J. Schlessinger,
S. R. Hubbard,
D. P. Smith,
C. Eng,
M. J. Lorenzo,
B. A. J. Ponder,
B. J. Mayer, and L. C. Cantley.
1995.
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.
Nature
373:536-539[Medline].
|
| 35.
|
Takahashi, M.,
Y. Buma,
T. Iwamoto,
Y. Inaguma,
H. Ikeda, and H. Hiai.
1988.
Cloning and expression of the ret protooncogene encoding a tyrosine kinase with two potential transmembrane domains.
Oncogene
3:571-578[Medline].
|
| 36.
|
Takahashi, M.,
Y. Buma, and H. Hiai.
1989.
Isolation of the ret proto-oncogene cDNA with an amino-terminal signal sequence.
Oncogene
4:805-806[Medline].
|
| 37.
|
Takahashi, M.,
N. Asai,
T. Iwashita,
T. Isomura, and K. Miyazaki.
1993.
Characterization of the RET proto-oncogene products expressed in mouse L cells.
Oncogene
6:297-301.
|
| 38.
|
Treanor, J.,
L. Goodman,
F. de Sauvage,
D. M. Stone,
K. T. Poulsen,
C. D. Beck,
C. Gray,
M. P. Armanini,
R. A. Pollock,
F. Hefti,
H. S. Phillips,
A. Goddard,
M. W. Moore,
A. Buj-Bello,
A. M. Davies,
N. Asai,
M. Takahashi,
R. Vandlen,
C. E. Henderson, and A. Rosenthal.
1996.
Characterization of a multicomponent receptor for GDNF.
Nature
382:80-83[Medline].
|
| 39.
|
Trupp, M.,
E. Arenas,
M. Fainzilber,
A. S. Nilsson,
B. A. Sieber,
M. Grigoriou,
C. Kilkenny,
E. S. Grueso,
V. Pachnis,
U. Arumae,
H. Sariola,
M. Saarma, and C. F. Ibanez.
1996.
Functional receptor for GDNF encoded by c-ret proto-oncogene.
Nature
381:785-789[Medline].
|
| 40.
|
Worby, C. A.,
Q. C. Vega,
Y. Zhao,
H. H. J. Chao,
A. F. Seasholtz, and J. E. Dixon.
1996.
Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase.
J. Biol. Chem.
271:23619-23622[Abstract/Free Full Text].
|
Mol Cell Biol, June 1998, p. 3321-3329, Vol. 18, No. 6
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Freche, B., Guillaumot, P., Charmetant, J., Pelletier, L., Luquain, C., Christiansen, D., Billaud, M., Manie, S. N.
(2005). Inducible Dimerization of RET Reveals a Specific AKT Deregulation in Oncogenic Signaling. J. Biol. Chem.
280: 36584-36591
[Abstract]
[Full Text]
-
Weber, F., Eng, C.
(2005). Editorial: Germline Variants within RET: Clinical Utility or Scientific Playtoy?. J. Clin. Endocrinol. Metab.
90: 6334-6336
[Full Text]
-
Lui, V. C.H., Leon, T. Y.Y., Garcia-Barcelo, M.-M., Ganster, R. W., Chen, B. L.S., Hutson, J. M., Tam, P. K.H.
(2005). Novel RET Mutation Produces a Truncated RET Receptor Lacking the Intracellular Signaling Domain in a 3-Generation Family with Hirschsprung Disease. Clin. Chem.
51: 1552-1554
[Full Text]
-
Jijiwa, M., Fukuda, T., Kawai, K., Nakamura, A., Kurokawa, K., Murakumo, Y., Ichihara, M., Takahashi, M.
(2004). A Targeting Mutation of Tyrosine 1062 in Ret Causes a Marked Decrease of Enteric Neurons and Renal Hypoplasia. Mol. Cell. Biol.
24: 8026-8036
[Abstract]
[Full Text]
-
Garcia-Barcelo, M-M, Sham, M-H, Lui, V C-H, Chen, B L-S, Song, Y-Q, Lee, W-S, Yung, S-K, Romeo, G, Tam, P K-H
(2003). Chinese patients with sporadic Hirschsprung's disease are predominantly represented by a single RET haplotype. J. Med. Genet.
40: e122-122
[Full Text]
-
Kjaer, S., Ibanez, C. F.
(2003). Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET. Hum Mol Genet
12: 2133-2144
[Abstract]
[Full Text]
-
Mardy, S., Miura, Y., Endo, F., Matsuda, I., Indo, Y.
(2001). Congenital insensitivity to pain with anhidrosis (CIPA): effect of TRKA (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine kinase for nerve growth factor. Hum Mol Genet
10: 179-188
[Abstract]
[Full Text]
-
Quadro, L., Fattoruso, O., Cosma, M. P., Verga, U., Porcellini, A., Libroia, A., Colantuoni, V.
(2001). Loss of Heterozygosity at the RET Protooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A. J. Clin. Endocrinol. Metab.
86: 239-244
[Abstract]
[Full Text]
-
Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K.-M., Johnson, M., Lynch, D., Tsien, R. Y., Lenardo, M. J.
(2000). Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations. Science
288: 2354-2357
[Abstract]
[Full Text]
-
Anders, J., Kjar, S., Ibanez, C. F.
(2001). Molecular Modeling of the Extracellular Domain of the RET Receptor Tyrosine Kinase Reveals Multiple Cadherin-like Domains and a Calcium-binding Site. J. Biol. Chem.
276: 35808-35817
[Abstract]
[Full Text]